Evercore ISI downgraded Zimmer Biomet to In Line from Outperform with a price target of $125, down from $135. While 4%-5% topline growth “has been telegraphed,” foreign exchange headwinds on margins will limit EPS growth, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $133 from $115 at Truist
- Zimmer Biomet price target lowered to $131 from $150 at Canaccord
- Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2023
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Zimmer Biomet price target raised to $125 from $120 at Morgan Stanley
